Sutro Biopharma and Vaxcyte finalize agreement triggering $5M payment; license amended

SUTRO BIOPHARMA, INC.

Vaxcyte agrees to pay Sutro $5.0M upon mutual agreement on Form Definitive Agreement, reached Sept 28, 2023.
Amendment No. 3 modifies royalty reduction provisions, IP ownership, prosecution, and financial reporting terms.
Vaxcyte gains rights to independently source cell-free extract from CMOs and option to internally manufacture extract.
Amendment effective immediately; negotiated under December 2022 letter agreement between the companies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.